What SeLux Diagnostics does

SeLux Diagnostics is a Boston-based medical device company founded in 2014 that has developed the Next-Generation Phenotyping (NGP) platform, a rapid antimicrobial susceptibility testing (AST) system. The platform delivers same-shift AST results, enabling clinicians to make personalized antibiotic treatment decisions within 24 hours rather than the multiple days required by traditional AST methods. The company targets U.S. hospitals and healthcare systems seeking faster infectious disease diagnostics to support antibiotic stewardship programs and address antimicrobial resistance.

The NGP platform is the company's sole commercial product, sold to U.S. hospitals through an enterprise field sales motion with revenue generated from instrument sales and related consumables/tests. Pricing is not publicly disclosed. The platform received FDA Breakthrough Device Designation in 2021, providing expedited regulatory review, and SeLux completed clinical trials prior to initiating its U.S. commercial launch. The company has positioned NGP as a potential new standard for infectious disease diagnostics, with go-to-market centered on hospitals requiring same-shift results to impact patient care and antimicrobial stewardship decisions.

SeLux has raised approximately $220 million in cumulative funding through April 2024 across multiple rounds, including a Series C ($50 million, February 2022) and a Series 3 ($48 million, April 2024), with equity investors including Northpond Ventures, RA Capital Management, Sands Capital Ventures, and Schooner Capital. Non-dilutive capital includes a BARDA contract potentially worth $60.8 million, a $30 million senior secured debt facility from Oxford Finance (June 2022), a $14.6 million BARDA award (June 2021), and a $2.8 million NIH grant (October 2021). Leadership comprises CEO Steve Lufkin, co-founders Aleksandar Vacic (President) and Eric Stern (CTO), and Chief Commercial Officer John Wilson, who leads the U.S. commercial team buildout.

Name

SeLux Diagnostics

Legal name

Selux Diagnostics

Website

https://seluxdx.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

SeLux Diagnostics is a Boston-based medical device company developing the Next-Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing, delivering same-shift results to U.S. hospitals to enable personalized antibiotic treatments within 24 hours.

Ownership category

akta.pro rank

Product category

Clinical Microbiology / In Vitro Diagnostics (Antimicrobial Susceptibility Testing)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category) (HLAHAOAH)

Keywords

• Antimicrobial susceptibility testing
• Infectious disease diagnostics
• Phenotyping diagnostic platform
• Clinical microbiology devices
• Rapid AST diagnostics

Headquarters

HQ city

Charlestown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Medical Device Diagnostics: Sale of rapid antimicrobial susceptibility testing platform and related consumables/tests for infectious disease diagnostics in healthcare settings

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

SeLux Diagnostics develops and commercializes the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing (AST) system that delivers same-shift phenotypic results so clinicians can select personalized antibiotic therapy within 24 hours. The platform combines a diagnostic instrument with proprietary consumables/tests and is intended to support infectious disease diagnosis and antibiotic stewardship in hospital and clinical microbiology settings.

Product overview

SeLux Diagnostics offers a single unified product: the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing system designed to provide same-shift AST results within 24 hours. The platform is intended to establish a new standard for infectious disease diagnostics by enabling personalized antibiotic treatments and supporting antibiotic stewardship programs. The company is commercializing this platform in the U.S. market following clinical trials and FDA breakthrough device designation.

Differentiator

Problem solved

Functional benefit

Brands

• Next-Generation Phenotyping (NGP) Platform: Rapid antimicrobial susceptibility testing platform that provides same-shift results for infectious disease diagnosis and antibiotic stewardship.

Products and services

• Next-Generation Phenotyping (NGP) Platform

Quantifiable outcome

• Results available same-shift, enabling personalized treatment within 24 hours

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Accelerate Diagnostics: Direct competitor in rapid phenotypic antimicrobial susceptibility testing; its Pheno system provides accelerated ID/AST results for bloodstream infections—the same clinical use case SeLux targets with NGP.
• Q-linea: Swedish developer of the ASTar rapid AST system, directly comparable as a same-shift phenotypic AST platform targeting hospital microbiology labs with high-throughput requirements.
• T2 Biosystems: Rapid molecular diagnostics company addressing bloodstream infections and sepsis with same-shift results; competes for the same hospital antimicrobial stewardship and time-to-treatment budget.

Emerging players

• Specific Diagnostics: Emerging competitor in rapid phenotypic AST using a proprietary metabolism-based technology, pursuing similar same-shift AST value proposition for hospital labs.

Broad incumbents

• BioMérieux: Global IVD incumbent with the VITEK automated AST system and extensive microbiology menu; competes broadly with SeLux through installed-base economics and is also developing faster AST solutions.
• Becton Dickinson (BD): Large diagnostics incumbent with BD Phoenix and BD MAX microbiology/AST systems and a broad installed base in hospital labs; comparable as both a competitor and potential strategic acquirer.

Others

• Copan Diagnostics: Specimen collection and automated sample-prep provider serving hospital microbiology labs; relevant as an ecosystem participant whose automation integrates with downstream AST platforms like NGP.

Regional players

• Hardy Diagnostics: U.S.-based microbiology supplies and culture media manufacturer with a regional footprint in clinical microbiology; comparable as an adjacent supplier into the same hospital lab customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SeluxDX
• LinkedInlinkedin.com/company/selux-diagnostics-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SeLux Diagnostics